Watchlist Manager

Watchlist

Price: 7.47 CNY -1.84%

Market Cap: ¥7.7B

B	Beijing SL Pharmaceutical Co Ltd SZSE:002038	CN

Income Statement

Currency: CNY

	Dec-2004	Mar-2005	Jun-2005	Sep-2005	Dec-2005	Mar-2006	Jun-2006	Sep-2006	Dec-2006	Mar-2007	Jun-2007	Sep-2007	Dec-2007	Mar-2008	Jun-2008	Sep-2008	Dec-2008	Mar-2009	Jun-2009	Sep-2009	Dec-2009	Mar-2010	Jun-2010	Sep-2010	Dec-2010	Mar-2011	Jun-2011	Sep-2011	Dec-2011	Mar-2012	Jun-2012	Sep-2012	Dec-2012	Mar-2013	Jun-2013	Sep-2013	Dec-2013	Mar-2014	Jun-2014	Sep-2014	Dec-2014	Mar-2015	Jun-2015	Sep-2015	Dec-2015	Mar-2016	Jun-2016	Sep-2016	Dec-2016	Mar-2017	Jun-2017	Sep-2017	Dec-2017	Mar-2018	Jun-2018	Sep-2018	Dec-2018	Mar-2019	Jun-2019	Sep-2019	Dec-2019	Mar-2020	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025
Revenue
Interest Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Revenue	93 N/A	92 -1%	102 +11%	111 +9%	119 +7%	127 +7%	134 +5%	137 +2%	146 +7%	151 +3%	175 +15%	208 +19%	238 +14%	268 +13%	300 +12%	342 +14%	358 +5%	371 +4%	369 -1%	372 +1%	390 +5%	404 +4%	437 +8%	424 -3%	458 +8%	495 +8%	521 +5%	577 +11%	623 +8%	662 +6%	744 +12%	822 +11%	1 007 +22%	1 072 +6%	1 150 +7%	1 201 +4%	1 162 -3%	1 219 +5%	1 204 -1%	1 229 +2%	1 243 +1%	1 232 -1%	1 195 -3%	1 169 -2%	1 157 -1%	1 138 -2%	1 090 -4%	1 032 -5%	1 010 -2%	977 -3%	1 004 +3%	1 085 +8%	1 242 +14%	1 456 +17%	1 757 +21%	2 019 +15%	2 168 +7%	2 193 +1%	2 237 +2%	2 192 -2%	2 030 -7%	1 759 -13%	1 517 -14%	1 296 -15%	1 113 -14%	1 171 +5%	1 200 +2%	1 184 -1%	1 215 +3%	1 237 +2%	1 144 -7%	1 128 -1%	1 050 -7%	1 072 +2%	1 079 +1%	1 000 -7%	1 018 +2%	967 -5%	827 -14%	782 -5%	660 -16%	584 -12%	573 -2%	579 +1%
Gross Profit
Cost of Revenue	(33)	(32)	(39)	(43)	(47)	(50)	(52)	(52)	(55)	(58)	(66)	(79)	(84)	(82)	(70)	(61)	(54)	(58)	(57)	(66)	(72)	(70)	(86)	(87)	(112)	(130)	(139)	(153)	(160)	(167)	(211)	(254)	(331)	(378)	(405)	(416)	(379)	(406)	(377)	(379)	(373)	(376)	(378)	(375)	(394)	(405)	(386)	(368)	(351)	(361)	(375)	(347)	(364)	(388)	(412)	(465)	(448)	(486)	(523)	(534)	(417)	(389)	(314)	(252)	(163)	(182)	(190)	(187)	(184)	(211)	(183)	(184)	(157)	(160)	(178)	(188)	(189)	(214)	(189)	(215)	(212)	(229)	(242)	(224)
Gross Profit	60 N/A	60 0%	63 +5%	67 +7%	72 +7%	77 +8%	82 +5%	85 +5%	91 +7%	94 +3%	109 +16%	130 +19%	153 +18%	186 +21%	230 +24%	282 +22%	305 +8%	312 +3%	312 0%	306 -2%	318 +4%	334 +5%	351 +5%	336 -4%	346 +3%	366 +6%	382 +5%	425 +11%	463 +9%	495 +7%	533 +8%	569 +7%	676 +19%	695 +3%	746 +7%	785 +5%	783 0%	813 +4%	828 +2%	850 +3%	870 +2%	856 -2%	817 -5%	794 -3%	763 -4%	734 -4%	704 -4%	664 -6%	659 -1%	617 -6%	629 +2%	738 +17%	878 +19%	1 068 +22%	1 345 +26%	1 555 +16%	1 719 +11%	1 707 -1%	1 714 +0%	1 659 -3%	1 612 -3%	1 370 -15%	1 202 -12%	1 045 -13%	949 -9%	989 +4%	1 010 +2%	997 -1%	1 031 +3%	1 025 -1%	962 -6%	944 -2%	893 -5%	912 +2%	901 -1%	812 -10%	830 +2%	753 -9%	638 -15%	567 -11%	448 -21%	355 -21%	331 -7%	355 +7%
Operating Income
Operating Expenses	(26)	(27)	(29)	(30)	(38)	(41)	(42)	(43)	(41)	(40)	(45)	(52)	(59)	(64)	(65)	(67)	(71)	(76)	(73)	(71)	(78)	(85)	(87)	(89)	(88)	(91)	(101)	(101)	(97)	(105)	(99)	(98)	(146)	(146)	(170)	(183)	(179)	(170)	(153)	(163)	(158)	(142)	(152)	(140)	(184)	(184)	(187)	(204)	(203)	(206)	(238)	(322)	(497)	(600)	(788)	(930)	(1 059)	(1 047)	(1 063)	(1 070)	(1 124)	(1 017)	(1 002)	(915)	(786)	(811)	(777)	(764)	(803)	(790)	(752)	(761)	(743)	(733)	(685)	(639)	(606)	(529)	(493)	(473)	(416)	(412)	(401)	(369)
Selling, General & Administrative	(27)	(27)	(29)	(30)	(39)	(42)	(42)	(43)	(41)	(37)	(44)	(51)	(60)	(65)	(66)	(66)	(71)	(75)	(72)	(71)	(78)	(79)	(81)	(83)	(88)	(90)	(99)	(100)	(97)	(103)	(99)	(97)	(78)	(146)	(168)	(180)	(84)	(166)	(147)	(157)	(93)	(135)	(143)	(135)	(88)	(172)	(177)	(195)	(142)	(201)	(234)	(315)	(418)	(604)	(792)	(916)	(975)	(997)	(1 042)	(1 043)	(972)	(922)	(853)	(772)	(556)	(620)	(558)	(548)	(561)	(623)	(607)	(598)	(513)	(577)	(530)	(479)	(337)	(369)	(332)	(308)	(162)	(274)	(267)	(256)
Research & Development	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(74)	0	0	0	(88)	0	0	0	(59)	0	0	0	(92)	0	0	0	(55)	0	0	0	(74)	0	0	(19)	(67)	(62)	(85)	(103)	(122)	(134)	(141)	(125)	(181)	(206)	(236)	(231)	(185)	(188)	(155)	(172)	(151)	(159)	(159)	(166)	(164)	(170)	(173)	(175)	(135)	(151)	(145)	(126)
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(7)	0	0	0	(7)	0	0	0	(7)	0	0	0	(7)	0	0	0	(7)	0	0	0	(13)	0	0	0	(38)	0	0	0	(59)	0	0	0	(62)	0	0	0	(73)	0	0	0	(86)	0	0	0	(118)	0	0	0	(131)	0	0	0
Other Operating Expenses	1	0	0	1	1	1	0	(0)	0	(2)	(2)	(1)	0	1	1	(1)	0	(1)	(0)	(0)	0	(6)	(6)	(6)	0	(1)	(1)	(1)	(0)	(2)	(0)	(1)	13	(1)	(2)	(2)	(0)	(4)	(6)	(6)	(0)	(7)	(8)	(4)	4	(13)	(10)	(10)	1	(5)	(4)	(7)	8	5	4	5	20	11	64	76	29	39	(9)	(19)	13	15	17	15	16	20	10	10	6	4	3	6	12	11	12	10	12	12	11	13
Operating Income	34 N/A	33 -3%	34 +3%	38 +11%	34 -11%	37 +10%	40 +8%	42 +5%	50 +19%	54 +9%	64 +17%	78 +22%	94 +21%	122 +29%	165 +35%	215 +30%	233 +9%	237 +1%	239 +1%	235 -2%	240 +2%	249 +4%	265 +6%	247 -7%	258 +4%	274 +6%	282 +3%	323 +15%	366 +13%	390 +7%	434 +11%	471 +9%	530 +13%	548 +3%	576 +5%	602 +5%	603 +0%	643 +7%	675 +5%	687 +2%	712 +4%	714 +0%	665 -7%	654 -2%	579 -12%	549 -5%	517 -6%	460 -11%	455 -1%	411 -10%	391 -5%	417 +7%	381 -8%	468 +23%	557 +19%	625 +12%	660 +6%	659 0%	651 -1%	589 -10%	488 -17%	353 -28%	200 -43%	130 -35%	163 +26%	177 +9%	233 +31%	233 +0%	229 -2%	235 +3%	210 -11%	183 -13%	150 -18%	179 +20%	217 +21%	173 -20%	223 +29%	224 +0%	145 -35%	94 -35%	32 -66%	(57) N/A	(70) -22%	(14) +79%
Pre-Tax Income
Interest Income Expense	2	2	3	4	5	4	4	4	7	15	21	38	45	31	23	6	(4)	6	17	23	29	26	20	24	24	30	251	246	229	230	17	20	25	38	41	42	44	56	56	62	68	82	99	88	78	39	13	22	54	70	85	118	136	223	212	166	22	39	33	55	73	50	181	212	250	274	293	310	226	183	82	45	108	249	224	185	254	94	1	7	(152)	(85)	71	89
Non-Reccuring Items	0	0	0	0	0	0	0	0	(2)	0	0	0	1	0	0	0	(0)	0	0	0	(6)	0	0	0	(1)	0	0	0	(2)	0	0	0	0	0	0	0	7	0	0	0	0	0	0	0	0	0	0	0	(3)	0	0	0	104	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	0	3	0	5	0	0	0	0	0	0	0	0	0	(0)	(0)
Gain/Loss on Disposition of Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(0)	0	0	0	(0)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Other Income	0	0	0	0	0	0	0	0	1	1	1	2	9	12	12	13	7	7	8	7	10	8	11	12	38	37	33	31	11	13	13	15	5	10	20	18	19	20	19	31	32	26	24	16	12	15	11	10	20	20	25	22	1	(3)	(10)	(11)	(10)	(10)	(10)	(10)	0	0	(0)	0	(0)	0	0	(0)	0	0	0	0	(4)	(4)	(4)	(4)	(13)	(13)	(13)	(18)	(14)	(14)	(17)	(12)
Pre-Tax Income	35 N/A	36 +1%	38 +6%	42 +11%	38 -9%	41 +8%	44 +7%	46 +5%	55 +19%	70 +27%	86 +22%	117 +36%	149 +27%	164 +10%	201 +22%	234 +17%	236 +1%	250 +6%	264 +5%	265 +1%	273 +3%	284 +4%	295 +4%	283 -4%	320 +13%	342 +7%	566 +66%	601 +6%	605 +1%	632 +5%	463 -27%	506 +9%	560 +11%	596 +6%	637 +7%	662 +4%	674 +2%	718 +7%	750 +4%	780 +4%	812 +4%	821 +1%	787 -4%	758 -4%	669 -12%	603 -10%	541 -10%	492 -9%	527 +7%	501 -5%	500 0%	557 +11%	623 +12%	688 +11%	759 +10%	780 +3%	672 -14%	688 +3%	674 -2%	634 -6%	561 -11%	402 -28%	381 -5%	342 -10%	413 +21%	451 +9%	525 +16%	546 +4%	458 -16%	419 -8%	296 -29%	229 -22%	259 +13%	424 +64%	437 +3%	354 -19%	465 +31%	305 -34%	133 -56%	83 -38%	(134) N/A	(157) -17%	(16) +90%	62 N/A
Net Income
Tax Provision	(3)	(3)	(4)	(5)	(5)	(5)	(5)	(6)	(8)	(10)	(7)	(11)	(14)	(16)	(22)	(31)	(18)	(19)	(23)	(18)	(29)	(31)	(35)	(33)	(43)	(46)	(74)	(80)	(80)	(85)	(64)	(69)	(80)	(85)	(92)	(95)	(102)	(106)	(107)	(113)	(111)	(110)	(116)	(100)	(92)	(85)	(70)	(77)	(80)	(76)	(74)	(81)	(94)	(103)	(112)	(107)	(108)	(108)	(107)	(103)	(81)	(61)	(58)	(56)	(51)	(60)	(61)	(54)	(37)	(25)	(9)	(6)	(31)	(57)	(55)	(44)	(50)	(22)	(5)	(2)	58	58	33	21
Income from Continuing Operations	32	32	34	37	34	37	39	41	48	61	80	106	135	148	179	203	218	231	240	247	244	253	260	250	276	296	492	521	524	547	399	437	480	511	544	566	572	612	643	667	701	711	671	658	577	519	470	415	447	424	426	476	529	585	647	673	563	581	567	531	480	341	323	286	362	391	464	492	421	394	287	224	228	368	381	310	415	283	128	81	(75)	(99)	17	83
Income to Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	(0)	(0)	(1)	(1)	(1)	(0)	0	0	1	1	1	(4)	(4)	(5)	(4)	(1)	(1)	(2)	(4)	1	1	5	6	5	5	0	1	(6)	(6)	(5)	(5)	(2)	(1)	2	1	5	6	5	10	5	4	4	2	8	9	11	12	7	6	3	1	3	4	5	6	5	3	3	4	6	5	5	4	2	2	2	1	1	1	1	1
Net Income (Common)	32 N/A	32 +1%	34 +6%	37 +8%	34 -8%	36 +8%	39 +7%	41 +5%	48 +17%	61 +27%	80 +32%	106 +33%	135 +27%	148 +9%	179 +21%	202 +13%	218 +8%	230 +6%	240 +4%	247 +3%	244 -1%	254 +4%	261 +3%	251 -4%	273 +9%	292 +7%	488 +67%	517 +6%	523 +1%	547 +4%	397 -27%	433 +9%	481 +11%	512 +6%	550 +7%	572 +4%	577 +1%	617 +7%	643 +4%	668 +4%	695 +4%	705 +1%	667 -5%	653 -2%	575 -12%	518 -10%	472 -9%	416 -12%	452 +9%	430 -5%	431 +0%	486 +13%	534 +10%	589 +10%	651 +11%	675 +4%	571 -15%	590 +3%	578 -2%	543 -6%	487 -10%	348 -29%	327 -6%	287 -12%	365 +27%	395 +8%	470 +19%	497 +6%	426 -14%	397 -7%	290 -27%	228 -21%	234 +3%	373 +59%	386 +4%	314 -19%	417 +33%	285 -32%	129 -55%	82 -36%	(74) N/A	(98) -33%	17 N/A	84 +382%
EPS (Diluted)	0.03 N/A	0.04 +33%	0.04 N/A	0.04 N/A	0.03 -25%	0.04 +33%	0.04 N/A	0.04 N/A	0.05 +25%	0.05 N/A	0.07 +40%	0.1 +43%	0.13 +30%	0.14 +8%	0.17 +21%	0.19 +12%	0.21 +11%	0.23 +10%	0.24 +4%	0.25 +4%	0.24 -4%	0.25 +4%	0.26 +4%	0.25 -4%	0.27 +8%	0.28 +4%	0.47 +68%	0.5 +6%	0.51 +2%	0.54 +6%	0.39 -28%	0.42 +8%	0.47 +12%	0.5 +6%	0.54 +8%	0.56 +4%	0.56 N/A	0.59 +5%	0.61 +3%	0.64 +5%	0.69 +8%	0.69 N/A	0.66 -4%	0.65 -2%	0.56 -14%	0.52 -7%	0.47 -10%	0.41 -13%	0.44 +7%	0.41 -7%	0.41 N/A	0.46 +12%	0.52 +13%	0.57 +10%	0.63 +11%	0.66 +5%	0.56 -15%	0.58 +4%	0.57 -2%	0.53 -7%	0.47 -11%	0.33 -30%	0.31 -6%	0.27 -13%	0.36 +33%	0.38 +6%	0.45 +18%	0.48 +7%	0.41 -15%	0.39 -5%	0.28 -28%	0.22 -21%	0.23 +5%	0.36 +57%	0.38 +6%	0.31 -18%	0.41 +32%	0.28 -32%	0.13 -54%	0.08 -38%	-0.07 N/A	-0.1 -43%	0.02 N/A	0.08 +300%

Income Statement Balance Sheet Cash Flow Statement

Beijing SL Pharmaceutical Co Ltd
SZSE:002038

Income Statement

Earnings Waterfall
Beijing SL Pharmaceutical Co Ltd

Income Statement
Beijing SL Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Beijing SL Pharmaceutical Co Ltd SZSE:002038

Income Statement

Earnings Waterfall Beijing SL Pharmaceutical Co Ltd

Income Statement Beijing SL Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Beijing SL Pharmaceutical Co Ltd
SZSE:002038

Earnings Waterfall
Beijing SL Pharmaceutical Co Ltd

Income Statement
Beijing SL Pharmaceutical Co Ltd